Active Biotech is a biotechnology company focused on autoimmune/inflammatory diseases and cancer. The company has three projects in pivotal phase: laquinimod, an orally administered small molecule with unique immunomodulatory properties for treating multiple sclerosis; TASQ for prostate cancer; and ANYARA, which is primarily for the treatment of renal cell cancer. Laquinimod is additionally in Phase II development for Crohn’s and lupus. For more information, visit the company’s Web site at www.activebiotech.com.